News articles about Zymeworks (NASDAQ:ZYME) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zymeworks earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6176936322417 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s rankings:

Zymeworks (NASDAQ:ZYME) traded up 0.31% on Tuesday, hitting $6.50. The company’s stock had a trading volume of 2,180 shares. The stock’s market cap is $162.11 million. The firm has a 50 day moving average of $7.99 and a 200-day moving average of $9.97. Zymeworks has a 12 month low of $6.25 and a 12 month high of $14.25.

Zymeworks (NASDAQ:ZYME) last posted its earnings results on Monday, May 15th. The company reported ($1.13) earnings per share for the quarter. Zymeworks had a negative net margin of 6,924.35% and a negative return on equity of 798,487.60%. The company had revenue of $0.23 million during the quarter. On average, analysts expect that Zymeworks will post ($2.75) earnings per share for the current fiscal year.

ZYME has been the topic of several recent analyst reports. Citigroup Inc. initiated coverage on Zymeworks in a research report on Tuesday, May 23rd. They set a “buy” rating and a $18.00 price target on the stock. Barclays PLC initiated coverage on Zymeworks in a research report on Tuesday, May 23rd. They set an “overweight” rating and a $20.00 price target on the stock. Wells Fargo & Company initiated coverage on Zymeworks in a research report on Tuesday, May 23rd. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Canaccord Genuity initiated coverage on Zymeworks in a research report on Tuesday, May 23rd. They set a “buy” rating and a $18.00 price target on the stock.

COPYRIGHT VIOLATION WARNING: “Zymeworks (NASDAQ:ZYME) Earning Somewhat Favorable Press Coverage, Study Finds” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/08/zymeworks-nasdaqzyme-earning-somewhat-favorable-press-coverage-study-finds.html.

About Zymeworks

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.

Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.